Cargando…

Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform—Analysis of Production and Immunogenicity

Feline leukemia virus (FeLV) is one of the most prevalent infectious diseases in domestic cats. Although different commercial vaccines are available, none of them provides full protection. Thus, efforts to design a more efficient vaccine are needed. Our group has successfully engineered HIV-1 Gag-ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortiz, Raquel, Barajas, Ana, Pons-Grífols, Anna, Trinité, Benjamin, Tarrés-Freixas, Ferran, Rovirosa, Carla, Urrea, Victor, Barreiro, Antonio, Gonzalez-Tendero, Anna, Cardona, Maria, Ferrer, Laura, Clotet, Bonaventura, Carrillo, Jorge, Aguilar-Gurrieri, Carmen, Blanco, Julià
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219511/ https://www.ncbi.nlm.nih.gov/pubmed/37240371 http://dx.doi.org/10.3390/ijms24109025

Ejemplares similares

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2023)

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
por: Pradenas, Edwards, et al.
Publicado: (2023)

Comparative efficacy of the Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV vaccines against infection with circulating feline Calicivirus
por: Almeras, T., et al.
Publicado: (2017)

Acute monoblastic leukemia in a FeLV-positive cat
por: Prihirunkit, Kreangsak, et al.
Publicado: (2008)

Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression
por: Patel, M., et al.
Publicado: (2015)

Regulation of FeLV-945 by c-Myb binding and CBP recruitment to the LTR
por: Finstad, Samantha L, et al.
Publicado: (2004)

Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection
por: Major, Andrea, et al.
Publicado: (2009)

Diseases associated with spontaneous feline leukemia virus (FeLV) infection in cats
por: Reinacher, M.
Publicado: (1989)

Comparative measurement of FeLV load in hemolymphatic tissues of cats with hematologic cytopenias
por: Abdollahi-Pirbazari, Mehdi, et al.
Publicado: (2019)

Could Phylogenetic Analysis Be Used for Feline Leukemia Virus (FeLV) Classification?
por: Cano-Ortiz, Lucía, et al.
Publicado: (2022)

Molecular characterization of Brazilian FeLV strains in São Luis, Maranhão Brazil
por: Martins, Nathálya dos Santos, et al.
Publicado: (2023)

Abrogation of contaminating RNA activity in HIV-1 Gag VLPs
por: Valley-Omar, Ziyaad, et al.
Publicado: (2011)

Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection
por: Hofmann-Lehmann, R., et al.
Publicado: (1995)

Development of antibodies to feline IFN-γ as tools to elucidate the cellular immune responses to FeLV
por: Graham, Elizabeth M., et al.
Publicado: (2003)

Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
por: Aguilar-Gurrieri, Carmen, et al.
Publicado: (2023)

Viral Determinants of FeLV Infection and Pathogenesis: Lessons Learned from Analysis of a Natural Cohort
por: Bolin, Lisa L., et al.
Publicado: (2011)

The Diagnosis of Feline Leukaemia Virus (FeLV) Infection in Owned and Group-Housed Rescue Cats in Australia
por: Westman, Mark, et al.
Publicado: (2019)

High prevalence of non-productive FeLV infection in necropsied cats and significant association with pathological findings
por: Suntz, M., et al.
Publicado: (2010)

Segregation of RD-114 and FeLV-related sequences in crosses between domestic cat and leopard cat
por: BENVENISTE, RAOUL E., et al.
Publicado: (1975)

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
por: Pradenas, Edwards, et al.
Publicado: (2022)

Complete Genome Sequence of Feline Leukemia Virus Kawakami-Theilen Strain KT-FeLV-UCD-1
por: Chin, Pei-Ju, et al.
Publicado: (2020)

Clinicopathological findings of FeLV- positive cats at a secondary referral center in Florida, USA (2008–2019)
por: Pare, Amelie, et al.
Publicado: (2022)

Difficulties in demonstrating long term immunity in FeLV vaccinated cats due to increasing age-related resistance to infection
por: Wilson, Stephen, et al.
Publicado: (2012)

Novel approach of dermatophytosis eradication in shelters: effect of Pythium oligandrum on Microsporum canis in FIV or FeLV positive cats
por: Načeradská, Martina, et al.
Publicado: (2021)

Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
por: Pradenas, Edwards, et al.
Publicado: (2022)

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
por: Trinité, Benjamin, et al.
Publicado: (2021)

Follow-Up of Viral Parameters in FeLV- or FIV-Naturally Infected Cats Treated Orally with Low Doses of Human Interferon Alpha
por: Gomez-Lucia, Esperanza, et al.
Publicado: (2019)

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
por: Pradenas, Edwards, et al.
Publicado: (2021)

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
por: Trinité, Benjamin, et al.
Publicado: (2021)

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2022)

Antibody induction after combined application of an adjuvanted recombinant FeLV vaccine and a multivalent modified live virus vaccine with a chlamydial component
por: Brunner, Chantal, et al.
Publicado: (2006)

A Four-Step Purification Process for Gag VLPs: From Culture Supernatant to High-Purity Lyophilized Particles
por: González-Domínguez, Irene, et al.
Publicado: (2021)

First description of a multisystemic and lethal SARS-CoV-2 variant of concern P.1 (Gamma) infection in a FeLV-positive cat
por: Carneiro, Rodrigo Lima, et al.
Publicado: (2022)

Intensifying Continuous Production of Gag-HA VLPs at High Cell Density Using Stable Insect Cells Adapted to Low Culture Temperature
por: Fernandes, Bárbara, et al.
Publicado: (2022)

114 VLPs and particle vaccines
por: Buonaguro, Luigi
Publicado: (2014)

RNA: packaged and protected by VLPs
por: Fang, Po-Yu, et al.
Publicado: (2018)

Chimeric VLPs Based on HIV-1 Gag and a Fusion Rabies Glycoprotein Induce Specific Antibodies against Rabies and Foot-and-Mouth Disease Virus
por: Fontana, Diego, et al.
Publicado: (2021)

Targeting of MuLV Gag to the plasma membrane is mediated by PI(4,5)P(2 )and PhosphatidylSerine
por: Hamard-Peron, E, et al.
Publicado: (2009)

Packaging of actin into Ebola virus VLPs
por: Han, Ziying, et al.
Publicado: (2005)

Functional RNAs: combined assembly and packaging in VLPs
por: Fang, Po-Yu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_64eu5a22m36lml2lperguredr7